LVTX
Price:
$1.6
Market Cap:
$42.07M
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody...[Read more]
Industry
Biotechnology
IPO Date
2021-03-26
Stock Exchange
NASDAQ
Ticker
LVTX
According to LAVA Therapeutics N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 6.39. This represents a change of -0.27% compared to the average of 6.41 of the last 4 quarters.
The mean historical Current Ratio of LAVA Therapeutics N.V. over the last ten years is 10.34. The current 6.39 Current Ratio has changed 6.08% with respect to the historical average. Over the past ten years (40 quarters), LVTX's Current Ratio was at its highest in in the December 2021 quarter at 30.80. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
10.34
Median
6.40
Minimum
2.54
Maximum
30.80
Discovering the peaks and valleys of LAVA Therapeutics N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.11%
Maximum Annual Current Ratio = 30.80
Minimum Annual Increase = -79.22%
Minimum Annual Current Ratio = 2.54
Year | Current Ratio | Change |
---|---|---|
2023 | 6.62 | 3.40% |
2022 | 6.40 | -79.22% |
2021 | 30.80 | 1.11% |
2020 | 2.54 | -52.51% |
The current Current Ratio of LAVA Therapeutics N.V. (LVTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
14.61
5-year avg
10.34
10-year avg
10.34
LAVA Therapeutics N.V.’s Current Ratio is greater than Anebulo Pharmaceuticals, Inc. (3.45), less than PMV Pharmaceuticals, Inc. (13.98), greater than Miromatrix Medical Inc. (3.46), greater than ZIVO Bioscience, Inc. (0.17), greater than Bionomics Limited (3.30), less than Edgewise Therapeutics, Inc. (26.35), less than Ikena Oncology, Inc. (15.32), less than Design Therapeutics, Inc. (34.61), greater than Xilio Therapeutics, Inc. (1.67), less than Eliem Therapeutics, Inc. (60.41), less than Aerovate Therapeutics, Inc. (8.78), greater than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (12.75), less than Rezolute, Inc. (13.79), less than AN2 Therapeutics, Inc. (9.75), greater than Generation Bio Co. (6.34), less than Kronos Bio, Inc. (8.32), less than Erasca, Inc. (11.00), greater than C4 Therapeutics, Inc. (6.31), less than Neoleukin Therapeutics, Inc. (15.33), less than Instil Bio, Inc. (12.90), greater than Achilles Therapeutics plc (6.04), less than NextCure, Inc. (9.07), greater than Assembly Biosciences, Inc. (2.36),
Company | Current Ratio | Market cap |
---|---|---|
3.45 | $37.86M | |
13.98 | $83.31M | |
3.46 | $92.95M | |
0.17 | $74.08M | |
3.30 | $5.75M | |
26.35 | $3.05B | |
15.32 | $82.52M | |
34.61 | $318.21M | |
1.67 | $39.21M | |
60.41 | $342.68M | |
8.78 | $76.81M | |
2.50 | $97.11M | |
12.75 | $202.87M | |
13.79 | $284.50M | |
9.75 | $39.99M | |
6.34 | $91.51M | |
8.32 | $54.49M | |
11.00 | $763.36M | |
6.31 | $300.00M | |
15.33 | $8.20M | |
12.90 | $170.65M | |
6.04 | $43.57M | |
9.07 | $33.33M | |
2.36 | $95.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like LAVA Therapeutics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like LAVA Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is LAVA Therapeutics N.V.'s Current Ratio?
How is the Current Ratio calculated for LAVA Therapeutics N.V. (LVTX)?
What is the highest Current Ratio for LAVA Therapeutics N.V. (LVTX)?
What is the 3-year average Current Ratio for LAVA Therapeutics N.V. (LVTX)?
What is the 5-year average Current Ratio for LAVA Therapeutics N.V. (LVTX)?
How does the current Current Ratio for LAVA Therapeutics N.V. (LVTX) compare to its historical average?